Drug intelligence / Profile preview

5-acetylsalicylic acid

Development stage: Preclinical
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral, Rectal, Intravenous

Overview

5-acetylsalicylic acid, also known as 5-acetyl-2-hydroxybenzoic acid, is a chemical compound exhibiting anti-inflammatory properties. It has been investigated in clinical settings as a potential treatment for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. While its precise molecular mechanism of action is not fully elucidated, its anti-inflammatory effects suggest involvement in pathways related to inflammation. It is primarily identified as a research chemical and is not listed as an approved pharmaceutical drug for human consumption by suppliers like TargetMol.

Other names: 5-acetyl-2-hydroxybenzoic acid

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)COX-3 (Prostaglandin-endoperoxide synthase 1 splice variant)

Beyond the preview

Go deeper on 5-acetylsalicylic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-acetylsalicylic acid.

Explore the full profile